Sergio España | Lightnews

Nature Communications @natcomms.nature.com · May 13

Plasma exchange therapy for the post #COVID19 condition: a phase II, double-blind, placebo-controlled, randomized trial

@ecuetosergio.bsky.social @lmateu.bsky.social @fundaciolluita.bsky.social

#LongCOVID #ClinicalTrial

Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications

Here, the authors report results from a clinical trial testing whether therapeutic plasma exchange (TPE) can help people with post-COVID-19 condition (PCC). While TPE had a favorable safety profile, it didn’t improve symptoms or quality of life for people with PCC.

bit.ly

2 5

Nature Communications @natcomms.nature.com · May 9

Plasma exchange therapy for the post #COVID19 condition: a phase II, double-blind, placebo-controlled, randomized trial

@ecuetosergio.bsky.social @lmateu.bsky.social @fundaciolluita.bsky.social

#LongCOVID #ClinicalTrial

Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications

Here, the authors report results from a clinical trial testing whether therapeutic plasma exchange (TPE) can help people with post-COVID-19 condition (PCC). While TPE had a favorable safety profile, it didn’t improve symptoms or quality of life for people with PCC.

bit.ly

2 7

Fundació Lluita contra les Infeccions @fundaciolluita.bsky.social · May 2

🆕 El Dr. @ecuetosergio.bsky.social participarà en l’estudi #SchistoM a Zàmbia, liderat per la Dra. Amaya Bustinduy (@lshtm.bsky.social) i amb col·laboració de #Zambart.

🎯 Millorar el diagnòstic de l’esquistosomiasi genital masculina, una infecció que afecta +250M de persones al món.

1 1

Sergio España-Cueto @ecuetosergio.bsky.social · Apr 15

We just wrapped up our trial on plasmapheresis for Long COVID. The results? Not what we hoped - safe, yes, but no real benefit over placebo. Still, this is progress. Every answer, even a “no,” gets us closer to what does work! 💪🏼

@fundaciolluita.bsky.social

lluita.org/es/ensayo-cl...

El ensayo clínico que estudiaba la plasmaféresis para tratar la covid persistente concluye que esta técnica no es eficaz

Medio centenar de pacientes con esta enfermedad han participado en un estudio pionero realizado por investigadores del Hospital Germans Trias y de la Fundació Lluita contra les Infeccions. Éste ha per...

lluita.org

1 6

Fundació Lluita contra les Infeccions @fundaciolluita.bsky.social · Apr 14

Un estudi de la Fundació, publicat a @naturecomms.bsky.social, confirma que la plasmafèresi és segura, però no aporta beneficis clínics en el tractament de la #COVIDpersistent.

lluita.org/lassaig-clin...

#Recerca @lmateu.bsky.social @ecuetosergio.bsky.social

1 1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 22

#Schistosomiasis #Parasitology #GlobalHealth #InfectiousDiseases #Diagnostics #AIinMedicine #TropicalMedicine #NeglectedTropicalDiseases #PublicHealth #FrontiersinParasitology

1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 22

The AiDx Assist device offers a reliable and efficient alternative to manual microscopy. Its automation reduces the need for training and minimizes human error. The AiDx Assist device could enhance early detection and treatment, potencially transforming Schistosomiasis diagnosis in endemic regions.

1 1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 22

Look at this new study conducted in Nigeria, evaluating the AiDx Assist device designed to automate the detection of Schistosoma eggs in biological samples. The study and assessed the device’s performance in analyzing stool and urine samples in endemic regions 📊

www.frontiersin.org/journals/par...

Frontiers | Evaluation of the AiDx Assist device for automated detection of Schistosoma eggs in stool and urine samples in Nigeria

www.frontiersin.org

1 1 1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 21

#longcovid #postcovidcondition #covid19 #infectiousdiseases #research #naturecommunications #nature #covidpersistente #condicionpostcovid19

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 21

#Longcovid #Postcovidcondition #Research #NatureCommunications #highlights

@nature.com @naturecomms.bsky.social @lmateu.bsky.social @rutgerwalls.bsky.social @fundaciolluita.bsky.social

1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 21

☄️ Here is our recent publication!
www.nature.com/articles/s41...

Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications

Here, the authors report results from a clinical trial testing whether therapeutic plasma exchange (TPE) can help people with post-COVID-19 condition (PCC). While TPE had a favorable safety profile, i...

www.nature.com

1 1 2

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 21

The Editors’ Highlights showcase the 50 most outstanding papers in each field, emphasizing the significance of our research on post-COVID syndrome treatment.

Grateful to Nature Communications for this recognition and invite you to read and share our work with colleagues who may be interested !

1 1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 21

🚀Thrilled to share that our article “Plasma Exchange Therapy for the Post COVID-19 Condition: a Phase II, double-blind, placebo-controlled, randomized trial” has been selected as part of Nature Communications’ Editors’ Highlights in the Microbiology and ID category!

📌 www.nature.com/collections/...

Microbiology and infectious diseases

This page highlights recent articles on all aspects of bacteriology, mycology, parasitology and virology, covering the biology of pathogens, host-pathogen ...

www.nature.com

1 3 5

Liverpool School of Tropical Medicine @lstmnews.bsky.social · Mar 20

Schistosomiasis remains underdiagnosed, undertreated, and underestimated as an NTD.

In a new Lancet article Prof. Russell Stothard explores the urgent need for better diagnostics, treatment, and global investment to meet WHO’s 2030 targets.

Read his piece on this important topic: lstm.ac/4kCohK7

Schistosomiasis: the hidden struggle for diagnosis and control

Diagnostic dilemmaFor any disease, accurate diagnosis is the cornerstone of effective treatment and control. Yet, for schistosomiasis, existing diagnostic tools are far from perfect.Diagnosis is done

lstm.ac

4 7

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 18

PCR and UCP-LF CAA were more sensitive for S. haematobium, while PCR and POC-CCA worked best for S. mansoni. This suggests that different regions may need different testing strategies?

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 18

For S. mansoni:
• 59% (PCR)
• 55% (UCP-LF CAA)
• 54% (POC-CCA)

1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 18

For S. haematobium, detection rates were:
• 66% (PCR)
• 60% (UCP-LF CAA)
• 52% (POC-CCA)

1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 18

A new study evaluates the accuracy of 3 diagnostic tests for Schistosoma in endemic areas of Madagascar: PCR, UCP-LF CAA, and POC-CCA. The goal? Finding the most effective way to detect the infection and improve its control. Our real challenge!

idpjournal.biomedcentral.com/articles/10....

Detecting Schistosoma infections in endemic countries: a diagnostic accuracy study in rural Madagascar - Infectious Diseases of Poverty

Background Schistosoma haematobium and S. mansoni are endemic in Madagascar, but reliable diagnostic tools are often lacking, contributing to exacerbate transmission and morbidity. This study evaluate...

idpjournal.biomedcentral.com

1

Médicos Sin Fronteras España @msfespana.bsky.social · Mar 4

🌍✨ BUENA NOTICIA ✨
Un estudio internacional demuestra que la vacuna contra la #hepatitisE es eficaz con solo dos dosis.

Es un gran paso en la lucha contra esta enfermedad.

👉 https://a.msf.es/435KTMA

Nakia John está siendo vacunada contra la hepatitis E. Nakia tiene 16 años y vive en el campo de desplazados internos de Bentiu, en Sudán del Sur.

3 9

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 3

@naturecomms.bsky.social

1

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 3

These results highlight the need for continued research into therapeutic strategies for Long COVID and understanding its pathophysiology. Huge thanks to @lmateu.bsky.social, @rutgerwalls.bsky.social & the entire Long COVID team from @fundaciolluita.bsky.social for trusting me from the very beginning

2 1 3

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 3

Our findings confirmed that TPE is a safe procedure, with a similar safety profile in both groups. However, we did not observe any significant clinical improvements across the evaluated efficacy parameters compared to the placebo group

1 1 2

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 3

🟠 In this trial, 50 patients with Long COVID were randomized to receive 6 sessions of either Plasma Exchange or Placebo, with a 90D follow-up. Our primary endpoint was safety, and secondary endpoints functional status, symptomology, quality of life, neurocognitive symptoms, and analytical parameters

1 1 2

Sergio España-Cueto @ecuetosergio.bsky.social · Mar 3

Thrilled to share our latest study, now published in the prestigious journal Nature Communications! 📊 We conducted a phase II, double-blind, randomized, placebo-controlled trial to evaluate therapeutic plasma exchange as a potential treatment for Long COVID. 🧵👇

www.nature.com/articles/s41...

Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications

Here, the authors report results from a clinical trial testing whether therapeutic plasma exchange (TPE) can help people with post-COVID-19 condition (PCC). While TPE had a favorable safety profile, i...

www.nature.com

3 5 9

Sergio España-Cueto @ecuetosergio.bsky.social · Feb 21

According to the 2024 @NFID survey on respiratory diseases, many people still underestimate the risks of flu, COVID-19, and RSV. Despite the high disease burden, vaccination rates remain low. Remember! Prevention is key! #PublicHealth #Vaccines

📊 Full infographic here: www.nfid.org/wp-content/u...

www.nfid.org

Sergio España-Cueto @ecuetosergio.bsky.social · Feb 17

#GlobalHealth #NTDs #parasiticinfections

Sergio España-Cueto @ecuetosergio.bsky.social · Feb 17

This breakthrough, backed by the ALIVE trial from the STOP Consortium, marks a major step forward in tackling these neglected tropical disease. The STOP2030 project, funded by Global Health EDCTP3, will assess the safety and effectiveness of this combination in MDA campaigns in Kenya and Ghana 💪🏼

1

Sergio España-Cueto @ecuetosergio.bsky.social · Feb 17

🚨 Big news! The EMA has issued a positive scientific opinion on a new fixed-dose combination of albendazole and ivermectin for treating soil-transmitted helminth infections and lymphatic filariasis in people aged 5 and up 🌍💊

www.global-health-edctp3.europa.eu/news-and-eve...

New treatment against parasitic worm infections funded by EDCTP receives positive opinion by the European Medicines Agency

www.global-health-edctp3.europa.eu

1 1

Sergio España-Cueto @ecuetosergio.bsky.social · Feb 5

Registrations here:

adimyf.com/dermatropical/

Dermatropical - Adimyf

Segunda Edición DERMATOLOGÍA TROPICAL Peculiaridades diagnósticas en diferentes fototipos El plazo ha finalizado 14 de marzo 2025 de 08:30 horas a 20:00 horas REUNIÓN PRESENCIAL: H.U. 12 DE OCTUBRE Im...

adimyf.com

Sergio España-Cueto @ecuetosergio.bsky.social · Feb 5

I invite you all to join - either in person or online! The event will be held in Spanish and will cover key diagnostic challenges across different skin phototypes.

Sign up and don’t miss it!

#Dermatology #TropicalMedicine #Schistosomiasis #Dermalawi

1